SG11202101524RA - T cell receptor constructs and uses thereof - Google Patents

T cell receptor constructs and uses thereof

Info

Publication number
SG11202101524RA
SG11202101524RA SG11202101524RA SG11202101524RA SG11202101524RA SG 11202101524R A SG11202101524R A SG 11202101524RA SG 11202101524R A SG11202101524R A SG 11202101524RA SG 11202101524R A SG11202101524R A SG 11202101524RA SG 11202101524R A SG11202101524R A SG 11202101524RA
Authority
SG
Singapore
Prior art keywords
cell receptor
receptor constructs
constructs
cell
receptor
Prior art date
Application number
SG11202101524RA
Other languages
English (en)
Inventor
Vikram Juneja
Jaewon Choi
Original Assignee
Biontech Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc filed Critical Biontech Us Inc
Publication of SG11202101524RA publication Critical patent/SG11202101524RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202101524RA 2018-08-16 2019-08-16 T cell receptor constructs and uses thereof SG11202101524RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862764817P 2018-08-16 2018-08-16
US201962810112P 2019-02-25 2019-02-25
PCT/US2019/046876 WO2020037239A1 (fr) 2018-08-16 2019-08-16 Constructions de récepteurs de cellules t et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11202101524RA true SG11202101524RA (en) 2021-03-30

Family

ID=69525945

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101524RA SG11202101524RA (en) 2018-08-16 2019-08-16 T cell receptor constructs and uses thereof

Country Status (14)

Country Link
US (1) US20210340215A1 (fr)
EP (1) EP3837279A4 (fr)
JP (2) JP2021533777A (fr)
KR (1) KR20210074277A (fr)
CN (1) CN112888707A (fr)
AU (1) AU2019321608A1 (fr)
BR (1) BR112021002826A2 (fr)
CA (1) CA3109232A1 (fr)
IL (1) IL280718A (fr)
MX (1) MX2021001837A (fr)
PH (1) PH12021550307A1 (fr)
SG (1) SG11202101524RA (fr)
TW (1) TW202021982A (fr)
WO (1) WO2020037239A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104843A1 (fr) 2011-02-06 2012-08-09 Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science Récepteurs de lymphocytes t à maturation d'affinité et leur utilisation
BR112020025615A2 (pt) * 2018-06-19 2021-03-23 Biontech Us Inc. neoantígenos e usos dos mesmos
EP3914270A4 (fr) * 2019-01-25 2023-01-11 The Trustees of the University of Pennsylvania Compositions et procédés de ciblage de ras mutants
CN114026116A (zh) 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
WO2021257770A2 (fr) * 2020-06-17 2021-12-23 Tscan Therapeutics, Inc. Peptides immunodominants de sars-cov-2 et leurs utilisations
IL276599A (en) * 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
EP4196134A1 (fr) * 2020-08-13 2023-06-21 Rootpath Genomics, Inc. Compositions et procédés d'identification d'antigènes
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
WO2022158977A1 (fr) * 2021-01-21 2022-07-28 Erasmus University Medical Center Rotterdam Lymphocytes t destinés à être utilisés en thérapie
WO2022216574A1 (fr) * 2021-04-05 2022-10-13 Janssen Biotech, Inc. Récepteurs des lymphocytes t calr et jak2
TW202304964A (zh) * 2021-04-14 2023-02-01 美商帝斯肯醫療公司 Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途
WO2022225836A1 (fr) * 2021-04-21 2022-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs de lymphocytes t à restriction hla de classe i dirigés contre ras ayant une mutation q61k
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
AU2022271195A1 (en) * 2021-05-03 2023-11-02 Bluesphere Bio, Inc. T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1
WO2023077100A1 (fr) * 2021-10-29 2023-05-04 Yafei Hou Récepteur des lymphocytes t reconnaissant la mutation r175h dans p53 et son application
TW202400665A (zh) * 2022-05-13 2024-01-01 福瑞德哈金森腫瘤中心 對ras新生抗原具有專一性之結合蛋白及其用途
WO2023230014A1 (fr) * 2022-05-23 2023-11-30 Affini-T Therapeutics, Inc. Protéines de liaison et cellules modifiées spécifiques de néoantigènes et leurs utilisations
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
WO2024039576A2 (fr) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center Récepteurs de lymphocytes t ciblant des mutations ras et utilisations associées

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150104441A1 (en) * 2013-10-11 2015-04-16 Oslo Universitetssykehus Hf Identification of disease-driving antigens
CN107223134B (zh) * 2014-11-26 2021-11-16 美国卫生和人力服务部 抗突变的kras的t细胞受体
AU2016235251B2 (en) * 2015-03-23 2022-03-17 The Johns Hopkins University HLA-restricted epitopes encoded by somatically mutated genes
KR20180043800A (ko) * 2015-09-09 2018-04-30 이뮨 디자인 코포레이션 Ny-eso-1 특이적 tcrs 및 그의 사용 방법
US10556940B2 (en) * 2015-09-15 2020-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-Cw8 restricted mutated KRAS
KR20180129899A (ko) * 2016-03-31 2018-12-05 네온 테라퓨틱스, 인크. 신생항원 및 이것의 사용 방법
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体

Also Published As

Publication number Publication date
CA3109232A1 (fr) 2020-02-20
IL280718A (en) 2021-03-25
AU2019321608A1 (en) 2021-03-18
EP3837279A1 (fr) 2021-06-23
CN112888707A (zh) 2021-06-01
TW202021982A (zh) 2020-06-16
BR112021002826A2 (pt) 2021-05-04
KR20210074277A (ko) 2021-06-21
EP3837279A4 (fr) 2022-05-11
PH12021550307A1 (en) 2021-10-25
MX2021001837A (es) 2021-07-16
JP2021533777A (ja) 2021-12-09
WO2020037239A1 (fr) 2020-02-20
JP2024060024A (ja) 2024-05-01
US20210340215A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
IL280718A (en) T cell structures and their uses
IL274921A (en) BCMA-directed chimeric antigen receptor and uses thereof
IL271435A (en) t cell receptors
HK1258274A1 (zh) 抗體/t細胞受體嵌合構建體及其用途
SG10201913579WA (en) Chimeric antibody/t-cell receptor constructs and uses thereof
EP3630980A4 (fr) Préparation cellulaire de récepteurs antigéniques chimériques et utilisations de celle-ci
EP3564266A4 (fr) Nouveau récepteur chimère de l'antigène et utilisation correspondante
EP3472208C0 (fr) Récepteurs de lymphocytes t et leurs utilisations
IL271751A (en) T cell receptors and immunotherapy using them
EP3567049A4 (fr) Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
EP3733839A4 (fr) Cellule t modifiée par récepteur d'antigène chimère modifié par anticorps et leurs utilisations
IL257295B (en) Chimeric antigen receptors, and T cells in which expression of a chimeric antigen receptor is measured
SG11201909751TA (en) Human alpha fetoprotein-specific t cell receptors and uses thereof
EP3573660A4 (fr) Constructions améliorées de récepteur de lymphocytes t couplé à un anticorps et leurs utilisations thérapeutiques
IL276746A (en) Kir3dl3 as hhla2 receptor, anti-hhla2 antibodies and their uses
IL276556A (en) Cyclin A1-specific T cell receptors and uses thereof
SG11202001011XA (en) Chimeric antigen receptor and car-t cells that bind cxcr5
IL273247A (en) New cell row and its uses
EP3765491C0 (fr) Récepteurs de lymphocyte t inductibles et utilisations associées
GB2585607B (en) Chimeric antigen receptor and application thereof
GB201721831D0 (en) T cell antigen receptor chimera
GB201820078D0 (en) T cell receptors
AU2015903719A0 (en) Chimeric antigen receptor and uses thereof